MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT01344031 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Positive
Invasive Breast Carcinoma
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG: Akt Inhibitor MK2206
DRUG: Anastrozole
DRUG: Fulvestrant
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)